ACAAI Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. Manuscripts must be submitted online via the Annals of Allergy, Asthma & Immunology online manuscript submission and peer review system. Only manuscripts submitted through the above link will be considered for review. Manuscripts that do not adhere to the following requirements will be returned to the corresponding author before peer review is initiated. Any exception

Asthma remissions have been identified as a new treatment outcome and as based on experience with biologics. Remissions are defined as no symptoms, no exacerbations, no use of systemic corticosteroids, and stabilization (optimization) of lung functions; all these criteria need to be sustained for at least 1 year. This study discussed the evolution of remissions, the evolving criteria, and experiences in achieving remission after treatment with biologics. In severe, uncontrolled asthma, treatment with biologics has led to remissions in 20% to 35% of the subjects treated.

ACAAI Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. NOTICE: Rievent, our partner for the online-learning platform, are ending support for Microsoft’s Internet Explorer (IE11) browser on January 31, 2020. If you are currently using IE as your primary browser, we recommend switching to one of their supported browsers(Chrome, FireFox, Edge, or Safari), before you click on an exam below, which will connect you to the Rievent

Food allergy management has greatly evolved in the last several years, moving from passive approaches, such as strict food allergen avoidance, to more active treatments, including regulatory approval of the first specifically indicated immunotherapy product (for peanut) in 2020. In 2024, a second therapy, omalizumab, received regulatory approval for the treatment of 1 or more IgE-mediated food allergies, providing clinicians with multiple treatment options to offer patients and families. With this expanded armamentarium of food allergy treatment options, the practicing clinician requires detailed knowledge of benefits and risks of omalizumab, how omalizumab fits into the management landscape, and how to use shared decision-making to optimize therapy.

The intensity of the current Israel-Hamas war in the Gaza Strip is unprecedented, in a region which has already witnessed ample violence in the past decades. This war began on October 7, 2023, when southern Israel was invaded by Hamas, an internationally recognized terror group. The terrorists murdered more than 1400 people, took 240 hostages, and committed crimes such as torturing of civilians, sexual violence, and burning of living humans.1 This massacre triggered a full-scale war in Gaza and skirmishes in the north of Israel, including the Galilee region and southern Lebanon.